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Background: ACE inhibitor-induced angioedema is a rare, yet potentially fatal, drug side effect. Considering
nearly 40 million people are taking ACE inhibitors for their anti-hypertensive and renal-protective benefits, a
significant number of patients are at risk for this drug-induced angioedema. This review was performed to
evaluate the efficacy of icatibant as treatment for ACE inhibitor-induced angioedema. Strength of evidence
was evaluated using the GRADE tool.
Method: An exhaustive search of available medical literature was conducted using Medline, PubMed, ISI Web
of Science, EBM Reviews Multifile, and CINAHL. Inclusion and exclusion criteria were applied. At the time
of this review, no randomized control trials were published; therefore, this review focuses on case reports.
Results: During the exhaustive literature search, only two case reports were found regarding the use of
icatibant as treatment for ACE inhibitor-induced angioedema. Both studies included in the review showed
substantial reduction in time to complete resolution of symptoms from ACE inhibitor angioedema using
icatibant as compared to standard therapy. Only local-site reactions of erythema and pruritus were evident as
side-effects from icatibant therapy.
Conclusion: Despite the small sample size of the studies, the overall Moderate GRADE outcome, and the
limited statistical significance from these observational reports, icatibant appears to dramatically reduce time
to: 1) first symptom improvement, and 2) complete symptom resolution of angioedema, as compared to
standard therapy. Therefore, the clinical significance of icatibant as a treatment modality for ACE inhibitor
angioedema is noteworthy, and should be further investigated by randomized control trials.
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ABSTRACT 
 
Background:  ACE inhibitor-induced angioedema is a rare, yet potentially fatal, 
drug side effect.  Considering nearly 40 million people are taking ACE inhibitors for 
their anti-hypertensive and renal-protective benefits, a significant number of patients 
are at risk for this drug-induced angioedema. This review was performed to 
evaluate the efficacy of icatibant as treatment for ACE inhibitor-induced 
angioedema.  Strength of evidence was evaluated using the GRADE tool. 
 
Method:  An exhaustive search of available medical literature was conducted using 
Medline, PubMed, ISI Web of Science, EBM Reviews Multifile, and CINAHL. 
Inclusion and exclusion criteria were applied.  At the time of this review, no 
randomized control trials were published; therefore, this review focuses on case 
reports.  
 
Results:  During the exhaustive literature search, only two case reports were found 
regarding the use of icatibant as treatment for ACE inhibitor-induced angioedema.  
Both studies included in the review showed substantial reduction in time to 
complete resolution of symptoms from ACE inhibitor angioedema using icatibant as 
compared to standard therapy.  Only local-site reactions of erythema and pruritus 
were evident as side-effects from icatibant therapy. 
 
Conclusion:  Despite the small sample size of the studies, the overall Moderate 
GRADE outcome, and the limited statistical significance from these observational 
reports, icatibant appears to dramatically reduce time to: 1) first symptom 
improvement, and 2) complete symptom resolution of angioedema, as compared to 
standard therapy.  Therefore, the clinical significance of icatibant as a treatment 
modality for ACE inhibitor angioedema is noteworthy, and should be further 
investigated by randomized control trials.  
 
Keywords:  angiotensin converting enzyme, ACE inhibitor, angioedema, icatibant, 
and Firazyr 
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INTRODUCTION 
Background 
Angiotensin converting enzyme (ACE) inhibitors are a type of medication 
frequently prescribed to patients for the treatment of hypertension, heart failure, and 
kidney disease.  Through a series of complex mechanisms, ACE inhibitors help to 
decrease blood pressure and improve cardiac output.   
Naturally occurring in our body, angiotensin converting enzyme acts to 
increase blood pressure and to degrade bradykinin – a potent vasodilator and 
inflammatory modulator (Carey, 2010). Therefore, inhibition of angiotensin 
converting enzyme leads to lower blood pressure and increased levels of bradykinin 
(Bingham, 2010).  In the presence of ACE inhibition, bradykinin can accumulate and 
cause vasodilation, increased vascular permeability, and release of nitric oxide 
(Bingham, 2010).  This accumulation of bradykinin, causing vascular permeability, is 
thought to contribute to the drug side effect of angioedema. 
ACE inhibitor (ACEi)-associated angioedema is a rare, yet potentially life-
threatening, side effect of treatment with ACE inhibitors (Byrd, Adam, & Brown, 
2006).  Reactions range from mild to severe swelling of the face, lips, tongue, 
mouth, larynx, pharynx, soft palate, and subglottic tissue, which can make it difficult 
to breathe or swallow (Bingham, 2010).  ACE inhibitor-induced angioedema occurs 
in 0.1% to 2.2% of patients, and accounts for 20 to 30% of all angioedema cases 
presenting to emergency departments in both community and tertiary-care settings 
(Carey, 2010; Bingham, 2010). The risk for angioedema is greatest in the first 
month of treatment with an ACE inhibitor; but interestingly, the majority of cases 
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occur after 1 month of treatment – nearly 1/3 of angioedema cases present more 
than 6 months after initiation of ACE inhibitor therapy, and some patients have 
experienced angioedema occurring up to 10 years post-initiation of treatment (Byrd 
et al., 2006).   
The pathophysiology of ACE inhibitor-induced angioedema is similar to that 
of hereditary angioedema (HAE) in the aspect that they are both mediated by 
bradykinin (Bas et al., 2010).  Studies have shown icatibant – a bradykinin type 2 
receptor antagonist – to be effective in the treatment of hereditary angioedema 
(Byrd et al., 2006).  Icatibant has been approved by the European Medicines 
Agency for the treatment of HAE: 30mg of subcutaneous icatibant demonstrated 
rapid and stable relief from symptoms in cutaneous, abdominal or laryngeal HAE 
attacks (Gras, 2009).  Since the bradykinin-induced etiology is responsible for most 
of the symptoms relating to both HAE and ACE inhibitor-induced angioedema, it 
might be speculated that icatibant could also potentially be effective for ACEi 
angioedema.  However, no randomized control studies have been performed to test 
the efficacy of icatibant as treatment for ACE inhibitor-induced angioedema.   
Currently, no specific or designated treatment regimens exist for ACE 
inhibitor-induced angioedema.  Treatment modalities utilized for ACEi angioedema 
thus far, include airway support, antihistamines, steroids, and in more severe cases, 
epinephrine (Byrd et al., 2006).  Unfortunately, these treatment options have not 
always been effective, at times requiring patients to undergo intubation, 
tracheotomy or cricothyroidotomy (Bas et al., 2010).  This risk profile is frightening, 
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especially considering that these procedures are invasive, and require patients to 
undergo general anesthesia, which can implicate a host of new complications.  
ACE inhibitor angioedema is often overlooked or misdiagnosed, yet it is an 
important medical emergency because, if untreated, it may develop into a serious 
life-threatening condition (Bas et al., 2010).  Considering that there are nearly 40 
million people taking ACE inhibitors (Byrd et al., 2006), many of whom have an 
increased risk of a potentially fatal drug-induced angioedema, the discovery of a 
definitive, safe, evidence-based treatment for ACEi angioedema is essential.  
Icatibant may be the effective, therapeutic solution for ACEi angioedema that 
physicians need. 
Purpose of the Study 
The purpose of this paper is to perform a systematic review of the literature 
regarding the use of icatibant as treatment for ACE inhibitor-induced angioedema 
using the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) tool, developed by the GRADE working group, in order to grade the 
strength of recommendation (Guyatt et al., 2008). 
METHOD 
 
An extensive literature search was performed using Medline, PubMed, ISI 
Web of Science, EBM Reviews Multifile, and CINAHL databases. These databases 
were accessed through the Pacific University Library system. The following 
keywords were searched individually and in combination: “angiotensin converting 
enzyme”, “ACE inhibitor”, “angioedema”, “icatibant” and “Firazyr”. “Angioedema” 
was also searched in a title field. The search was limited to human subjects, the 
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English language, full text articles, and to articles published since the year 2000.  
The initial search results included two references from Medline, six from PubMed, 
five from ISI Web of Science, one from EBM Reviews Multifile, and zero from 
CINAHL.  Relevant articles were selected and cross-referenced for additional 
materials.  A total of 14 articles were yielded from these search results.  Duplication 
articles and articles that did not investigate icatibant or Firazyr as treatment 
modalities for ACE-inhibitor-associated angioedema were then excluded.  Limited 
research is available on this topic.  At the time of this review, there were no 
published randomized control studies.  Therefore, this systematic review included 
the only two studies which were relevant.  One study was a case series and one 
was a case study. 
RESULTS  
After the exhaustive literature search and application of inclusion and 
exclusion criteria, only two case report articles remained which met the search 
criteria.  The outcomes of these two case reports included: 1) time to first 
improvement of symptoms, and 2) time to complete symptom resolution.  A total of 
nine patients were reviewed.  In both case reports, all patients were adults, were 
taking ACE-inhibitors, and had an acute angioedema attack of the head or neck 
(tongue, larynx, and/or pharynx) of less than 10 hours duration.  Angioedema of 
etiologies other than ACE inhibitor-induced were excluded from the diagnosis.  In 
addition, all nine patients stopped taking their prescribed ACE inhibitors (either 
ramipril, enalapril, or fosinopril) once this etiology was identified as the cause of 
angioedema. 
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Time to First Improvement of Symptoms 
Bas et al. (2010) conducted a case series report using eight patients with 
acute ACEi-induced angioedema, treated with a single, subcutaneous injection of 
30mg icatibant.  The authors reported that the average time to first symptom 
improvement of the eight patients after icatibant administration was 50.6 minutes, 
with a standard deviation of 21 minutes.  No other additional interventions were 
used for these patients.  Based on these findings, the authors concluded that 
administration of 30mg subcutaneous icatibant quickly and reliably reduced time to 
first improvement of symptoms without necessitating any other interventions. 
Schmidt, Hirschl, and Trautinger (2010) described how one adult patient, 
taking the ACE inhibitor fosinopril, was admitted to the emergency unit with acute 
ACEi-induced angioedema.  Since this patient’s angioedema was refractory to initial 
treatment with intravenous methylprednisolone, intravenous diphenhydramine, 
inhaled epinephrine, and infusion of C1 esterase inhibitor concentrate, he was 
ultimately given a dose of 30mg subcutaneous icatibant.  The authors explained 
that emergency tracheotomy was considered for this patient, but was avoided, 
because 10 to 15 minutes after the administration of 30mg subcutaneous icatibant, 
the “situation began to improve” (Schmidt et al., 2010, p.913).  The authors 
concluded that treatment with antihistamines, corticosteroids, and epinephrine is 
often ineffective in treating ACE inhibitor-induced angioedema.  Furthermore, the 
authors recommend further investigation of icatibant in clinical trials, especially 
considering that a single dose of 30mg icatibant resulted in rapid symptom 
improvement and helped to prevent tracheotomy on this patient.  
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Time to Complete Symptom Resolution 
In the case series performed by Bas et al. (2010), complete symptom 
resolution was assessed by a physician.  This study defines complete symptom 
resolution as the complete recovery from all symptoms of angioedema, and 
associated with the discharge of the patient from the hospital, with no further drug 
treatment related to angioedema.  Bas et al. (2010) reported that the average time 
to complete symptom resolution of the eight patients after administration of 30mg 
subcutaneous icatibant was 4.4 hours, with a standard deviation of 0.8 hours.  No 
other additional interventions were used for these patients.   
Also evaluated by Bas et al. (2010) was a historical group of 47 patients, 
similarly diagnosed with ACEi-induced angioedema, and treated during the previous 
seven years with methylprednisolone and clemastine.  The authors considered 
these 47 patients to be the control group.  In this group of patients, the mean time to 
complete symptom resolution was 33 hours, with a standard deviation of 19.4 
hours.  Some of these patients underwent tracheotomy, were intubated, or received 
a second administration of corticosteroids (250-500mg methylprednisolone) due to 
symptom persistence or worsening. The authors concluded that administration of 
30mg subcutaneous icatibant resulted in quicker time to complete symptom 
resolution than standard therapy.  Thus, for a more effective achievement of 
complete symptom resolution from ACEi-induced angioedema, the authors 
recommend 30mg subcutaneous icatibant.   
Schmidt et al. (2010) explain in their case report that the one adult patient 
with acute ACEi-induced angioedema due to fosinopril experienced complete 
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resolution of airway obstruction within 10-15 minutes after injection of 30mg 
subcutaneous icatibant.  The authors concluded that, a single dose of 30mg 
subcutaneous icatibant results in rapid and complete symptom resolution, and 
should be investigated further in clinical trials as a treatment modality for ACE 
inhibitor-induced angioedema.  
Additional Study Information 
Bas et al. (2010) 
For all ACEi-induced angioedema patients, the authors found no sign of 
inflammation such as increased leukocyte count or increased body temperature, 
and there were no signs of infection during hospitalization.  
All patients in this study who were treated with icatibant developed mild, local 
injection-site reactions of erythema and pruritus; yet these local reactions resolved 
spontaneously within approximately two hours.  A 3-6 month follow-up stage after 
the study’s completion revealed no systemic or serious adverse events. 
Unfortunately, no records were kept as to how and when follow-up was conducted.  
In all patients in this case study, including the historical group, a flexible 
trans-nasal fiber-optic laryngoscopy was performed hourly to monitor edematous 
mucosa until symptom relief was achieved.  
Schmidt et al. (2010) 
 This study focused on one 42-year-old caucasian male taking the ACE 
inhibitor fosinopril.  Normal levels of C4 in this patient ruled out hereditary 
angioedema, and no other etiology of angioedema was elucidated, except for the 
ACE inhibitor.  The patient’s angioedema was refractory to treatment with 
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antihistamines, corticosteroids, and epinephrine.   Although the patient’s 
angioedema was responsive to 30mg subcutaneous icatibant, the authors did not 
address any adverse drug reactions or side-effects of icatibant therapy.  No follow-
up was mentioned at all for the patient in this study.  The authors did not assess 
signs of inflammation, infection, or use a laryngoscope to monitor edematous 
mucosa, as compared to Bas et al. (2010).   
DISCUSSION 
ACE inhibitor-induced angioedema is a rare, yet potentially fatal, side effect 
of taking a commonly prescribed anti-hypertensive medication.  Bas et al. (2010) 
demonstrated that in all eight patients with ACEi-induced angioedema, a simple 
subcutaneous injection of 30mg icatibant resulted in an average time to first 
improvement of symptoms within 50.6 minutes, and an average time to complete 
resolution of symptoms within 4.4 hours.  Comparatively, time to complete 
resolution of symptoms in the historical control group in this study, who had been 
prescribed standard treatment modalities of methylprednisolone and clemastine, 
had an average time to complete resolution of 33 hours.  Therefore, patients who 
received 30mg subcutaneous icatibant injection in this study experienced complete 
symptom resolution 7.5 times faster compared to standard therapy. This dramatic 
difference in time to complete symptom resolution can equate to an issue of life 
versus death for a patient.    
Schmidt et al. (2010) described how one adult male with ACEi-induced 
angioedema had tried all initial standard treatment modalities including 
corticosteroids, antihistamines, epinephrine, and a C1 esterase inhibitor, and he 
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was about to undergo emergency tracheotomy, when one subcutaneous injection of 
30mg icatibant resolved his symptoms within 10-15 minutes.  Quicker symptom 
resolution not only means improved quality of life, but also reduces the chances of 
patients needing to undergo surgical operations or general anesthesia, which can 
increase morbidity, extend hospitalization, increase chances of infection, and 
increase healthcare cost.   
One of course must consider the possible side effects of drug intervention.  
Indeed, icatibant has been shown to have side effects.  Fortunately, these drug 
reactions appear to be minimal and brief, and include only local-site reactions of 
erythema and pruritus, which are extremely tolerable, considering the alternative of 
ultimate tracheal intubation or tracheostomy.  No serious adverse events were 
associated with administration of icatibant.  
Limitations 
Limitations in these studies do exist.  In particular, the limited patient 
population (sample size) results in a low power and low probability of statistical 
significance.  The results of observational studies, such as these case reports, do 
not meet the level of rigor that randomized control trials contain. Unfortunately, no 
randomized control trials regarding icatibant as treatment for ACE inhibitor-induced 
angioedema were elucidated from the extensive literature search.  Additionally, the 
only ACE inhibitors that patients were taking in these case reports were ramipril, 
enalapril, and fosinopril.  Further research should be performed to delineate 
whether icatibant is effective at treating any type of ACE inhibitor-induced 
angioedema, regardless of which ACE inhibitor is prescribed.  An additional 
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limitation includes the fact that there was no specificity with regard to the follow-up 
of patients.  Bas et al. (2010) mentioned a follow-up period of 3-6 months after the 
study’s completion, but failed to specify how this was conducted; and Schmidt et al. 
(2010) did not address any follow-up protocol. These points should be considered if 
a prospective, randomized control trial is performed. 
GRADE 
To grade quality of evidence and strength of recommendation, the GRADE 
(Grading of Recommendations Assessment, Development and Evaluation) tool, 
developed by the GRADE working group, was used (Guyatt et al., 2008).  The 
comparison was icatibant versus standard therapy for treatment of ACE inhibitor-
induced angioedema (Appendix: Table 1).  GRADE was applied to two outcomes: 
1) time to first improvement of symptoms, and 2) time to complete symptom 
resolution.   
Time to first improvement of symptoms 
Using the first outcome of time to first improvement of symptoms, two case 
studies were used. Based on the study design of observational studies, which are 
inherently categorized as low quality of evidence, the two case reports used for this 
systematic review were evaluated with a starting grade of “Low.”  As defined by the 
GRADE working group, “Low” quality of evidence means: “further research is very 
likely to have an important impact on the confidence in the estimate of effect and is 
likely to change the estimate” (Guyatt et al., 2008, p. 926).  Only outcomes with the 
initial GRADE of high can be down-graded based on study quality, consistency, 
directness, precision or publication bias.  Outcomes with an initial GRADE of low 
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can be upgraded.  No increase in GRADE was awarded further for dose-response 
or confounders; however, based on large magnitude of clinical significance, the 
GRADE was updated to “Moderate”, which is defined as: “further research is likely 
to have an important impact on our confidence in the estimate of effect and may 
change the estimate” (Guyatt et al., 2008, p. 926). 
Time to complete symptom resolution 
Using the second outcome of time to complete symptom resolution, the same 
two case studies were examined.  Similarly, based on study design, the two case 
reports were evaluated with a starting grade of “Low.”  No increase in GRADE was 
awarded further for dose-response or confounders.  Nevertheless, the GRADE was 
updated to “Moderate” based on large magnitude of clinical significance.  
Based on criteria established by GRADE working group, the overall GRADE 
of evidence of the systematic review, across all outcomes, was “Moderate”.   
Conclusion and Implications for Practice 
Despite the limitations and the overall Moderate GRADE outcome, the 
clinical significance of this review is remarkable and noteworthy.  If one single, 
subcutaneous injection of 30mg icatibant can substantially reduce the time of 
complete symptom resolution from 33 hours to 4.4 hours, eliminate the need for 
surgical intervention or general anesthesia, decrease morbidity and mortality for 
patients, and cause no systemic or serious adverse events, then this drug should 
certainly be evaluated for approval to be used as first-line treatment for ACE 
inhibitor-induced angioedema.  A prospective, randomized control trial should be 
performed to confirm the findings of these observational studies.   
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